Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status (Q37964938)

26 August 2017

title

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status (English)

1 reference

26 August 2017

main subject

myelodysplastic syndrome

1 reference

H Joachim Deeg

1 reference

26 August 2017

Matthias Bartenstein

1 reference

26 August 2017

publication date

6 December 2011

1 reference

Archivum Immunologiae et Therapiae Experimentalis

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

31-41

1 reference

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Hematopoietic stem cell transplantation for MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Future of cord blood for oncology uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005–2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Transplantation conditioning regimens: can we say it better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Who is fit for allogeneic transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Optimization of allogeneic transplant conditioning: not the time for dogma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Reduced mortality after allogeneic hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Immunotherapy of multiple myeloma: the start of a long and tortuous journey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Unmanipulated or CD34 selected haplotype mismatched transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Ex vivo expansion of cord blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

The evolution of hematopoietic SCT in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Impact on survival of different treatments for myelodysplastic syndromes (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Searching for alternative hematopoietic stem cell donors for pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Haploidentical stem cell transplantation: the always present but overlooked donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

The myelodysplastic syndromes: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Iron overload in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Immunobiology of allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0152-Z

10.1007/S00005-011-0152-Z

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference